Abstract:Abstract Abstract 1466 Background: Histone acetyltransferases and histone deacetylases (HDAC) regulate gene expression through acetylation-deacetylation of histones. HDACs are the target of a family of compounds known as HDAC inhibitors, which have been shown to suppress pro-inflammatory cytokines and reduce acute graft-versus-host disease (GVHD) while preserving the graft-versus-leukemia (GVL) effect after allogeneic bone marrow transplantation (BMT) in mice. However, the role of individual HDAC members in the development of GVHD is not clear. Recently, HDAC11, the newest member of the HDAC family has emerged as an important transcriptional regulator of inflammatory responses in antigen-presenting cells (APCs)1. Here, we evaluated the role of HDAC11 on APCs and T cells in the allogeneic BMT setting in mice with genetic disruption of HDAC11. Method: Proliferation of wild-type (WT) and HDAC11 knock-out (KO) T cells in response to allogeneic antigens was compared by [H3] thymidine incorporation assay. Using the same method, we also tested the antigen presentation ability of WT and HDAC11 KO APCs. For in vivo studies, we used a clinical relevant mouse model of BMT: C57BL/6 (B6) ® BALB/c. To evaluate the role of HDAC11 in the function of T cells and APCs, WT and KO mice on B6 background were used as donors and recipients, respectively. Recipient survival was monitored daily and GVHD symptom was evaluated at least twice a week. HDAC11 KO mice were supplied by Merck and Co., Inc. Results: In vitro, HDAC11 KO T cells proliferated stronger than WT T cells under the stimulation of allogeneic APCs. Recipients of HDAC11 KO T cells lost significantly more body weight (p < 0.05), and died significantly sooner than those of WT T cells (p < 0.01). The pathologic score of KO recipients was higher than that of WT recipients in each of GVHD target organs including lung, liver, small intestine and colon. Mechanistically, we found that there were significantly more total and IFNγ-producing donor T cells in the recipients of KO cells than those of WT cells (p < 0.05). Collectively, HDAC11 KO T cells have higher activity in response to alloantigens in vitro and induced more severe GVHD in vivo compared to WT T cells. In contrast, KO and WT APCs had a similar ability to stimulate allogeneic T cells in vitro, and no significant difference in GVHD development was observed in WT or KO recipients after allogeneic BMT. Conclusion: HDAC11 negatively regulates T-cell function, but has no significant effect on APC function. This finding provides a rationale to promote T-cell immunity or tolerance by inhibiting or enhancing HDAC11, respectively. 1 Villagra et al. Nature Immunology, 10:92-100, 2009. Disclosures: No relevant conflicts of interest to declare.

HDAC inhibition prevents transgene expression downregulation and loss-of-function in T cell-receptor-transduced T cells

Rerovirus Mediated Hsv-Tk Gene Transfer Can Influence The Function Of Human T-Lymphocyte

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

Histone Deacetylase Inhibitors Directly Modulate T Cell Gene Expression and Signaling and Promote Development of Effector-Exhausted T Cells in Murine Tumors

Deletion of a Class IIb Histone/protein Deacetylase (HDAC), HDAC10, Enhances FoxP3+ T-regulatory (Treg) Cell Suppressive Function, Gene Expression and Metabolism, and Promotes Allograft Survival

Abstract 6595: HDAC8 targeting impairs Foxp3+Treg cell function and promotes anti-tumor immunity

T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function

Deacetylase Inhibition Promotes the Generation and Function of Regulatory T Cells.

Antitumor Activity from Antigen-Specific CD8 T Cells Generated in Vivo from Genetically Engineered Human Hematopoietic Stem Cells

Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

A Safe, Effective in Vivo Gene Therapy for Melanoma Using Tyrosinase Promoter-Driven Cytosine Deaminase Gene

HDAC1 acts as tumor suppressor in ALK-positive anaplastic large-cell lymphoma: Implications for HDAC inhibitor therapy

Targeting of Histone Deacetylases to Reactivate Tumour Suppressor Genes and Its Therapeutic Potential in a Human Cervical Cancer Xenograft Model

False-positive human immunodeficiency virus nuclear acid amplification technique testing following therapy with transgenic T cell receptor cellular therapy for synovial sarcoma

HDAC Inhibition Potentiates Anti-Tumor Activity of Macrophages and Enhances Anti-Pd-l1-mediated Tumor Suppression

Hdac11 Inhibits T-Cell Response To Alloantigens And Reduces Gvhd In Mice

T-cell Receptor Gene Therapy Targeting Melanoma-Associated Antigen-A4 by Silencing of Endogenous TCR Inhibits Tumor Growth in Mice and Human